Multiple sclerosis following SARS-CoV-2 infection

•The first case of multiple sclerosis (MS) shortly after COVID-19 is presented.•Viral infections strongly relate to MS onset and its relapses.•SARS-CoV-2 can play a role in the triggering of demyelinating diseases.•Systemic immune response against SARS-CoV-2 could reach CNS leading to demyelination....

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders Vol. 45; p. 102377
Main Authors: Palao, M., Fernández-Díaz, E., Gracia-Gil, J., Romero-Sánchez, C.M., Díaz-Maroto, I., Segura, T.
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01.10.2020
Subjects:
Adult
Betacoronavirus
Coronavirus Infections - complications
COVID-19
Demyelinating disease
Female
Humans
MHV-59
Multiple Sclerosis - epidemiology
Multiple Sclerosis - pathology
Neurology
Optic neuritis
Original
Pandemics
Pneumonia, Viral - complications
SARS-CoV-2
COVID-19
Demyelinating disease
SARS-CoV-2
MHV-59
Optic neuritis
ISSN:2211-0348, 2211-0356, 2211-0356
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The first case of multiple sclerosis (MS) shortly after COVID-19 is presented.•Viral infections strongly relate to MS onset and its relapses.•SARS-CoV-2 can play a role in the triggering of demyelinating diseases.•Systemic immune response against SARS-CoV-2 could reach CNS leading to demyelination. SARS-CoV-2 infection can produce neurological features. The most common are headache, anosmia and dysgeusia but patients may also develop other central nervous system (CNS) injuries. We present a patient affected by Covid-19 who initially consulted for decreased visual acuity. The MRI showed inflammation in the right optic nerve and demyelinating lesions in the CNS. We speculate that an immune mechanism induced by SARS-CoV-2, which can activate lymphocytes and an inflammatory response, plays a role in the clinical onset of the disease. This pathogen may be associated with either the triggering or the exacerbation of inflammatory/demyelinating disease.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2211-0348
2211-0356
2211-0356
DOI:10.1016/j.msard.2020.102377